An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

Description

This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney DiseaseAn open-label Phase 2 study is designed to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype.

Trial Eligibility

Key Inclusion Criteria: * APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2 * Chronic kidney disease with persistent albuminuria Key Exclusion Criteria: * Organ or bone marrow transplantation * History of cancer within past 2 years, excepted for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer * Conditions that may alter drug absorption, e.g., history of bariatric surgery * Type I diabetes * Pregnant or currently nursing Other inclusion/exclusion criteria defined in protocol apply.

Study Info

Interventions

Locations Recruiting

Interested in joining this trial?

Our dedicated patient navigators are here to support you by reviewing the eligibility criteria to see if you might qualify for this trial.